Shanghai Dermatology Hospital

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Psoriasis9 trials
• Atopic dermatitis (eczema)5 trials
• Vitiligo1 trial

Phase

• Phase 36 trials
• Phase 25 trials
• Phase 2/32 trials
• Phase 11 trial

Status

• Completed8 trials
• Not yet recruiting5 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Beijing InnoCare Pharma Tech Co., Ltd.3 trials
• Dermavon Holdings Limited2 trials
• Bambusa Therapeutics1 trial
• Guangdong Hengrui Pharmaceutical Co., Ltd1 trial
• Hansoh BioMedical R&D Company1 trial
• and 7 more

Running trials

• Not yet recruiting

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT07465120· Phase 2· Dermavon Holdings Limited· Source

  Contact: Shi Yuling Shanghai Dermatology Hospital

• Not yet recruiting

  A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

  NCT07432854· Phase 2/3· Dermavon Holdings Limited· Source

  Contact: YuLing Shi

• Recruiting

  A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

  NCT07239947· Phase 1· Bambusa Therapeutics· Source

  Contact: Yangfeng Ding

• Recruiting

  ICP-332 in Subjects With Non-segmental Vitiligo

  NCT07047612· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

  Contact: Yangfeng Ding

• Not yet recruiting

  A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

  NCT06926582· Phase 2· Hansoh BioMedical R&D Company· Source

  Contact: Yuling Shi, MD

• Active, not recruiting

  A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

  NCT06875934· Phase 2· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Recruiting

  Chinese Psoriasis Real World Evidence Research

  NCT04465838· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

  Contact: Yuling Shi, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriasis3 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

  NCT07251998· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

  NCT07746479· Phase 3· Livzon Pharmaceutical Group Inc.· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Completed

  Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

  NCT06554847· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Completed

  Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06477237· Phase 3· Huabo Biopharm Co., Ltd.· Source

• Completed

  Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

  NCT06109818· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source